Ipamorelin vs Sermorelin: Research Comparison

The short comparison

Ipamorelin vs sermorelin is a comparison of two peptides that both raise growth hormone but do it through completely different mechanisms — and that sit on opposite sides of the regulatory line. Ipamorelin is a ghrelin-receptor (GHS-R1a) agonist: it mimics the hunger hormone ghrelin to fire a sharp, selective growth-hormone pulse, and it has never been an approved drug ^[1][3]. Sermorelin is a GHRH analog — it copies the body's own growth-hormone-releasing hormone — and it was historically an FDA-approved drug (later withdrawn from the U.S. market for commercial reasons, not safety) for diagnosing and treating growth-hormone deficiency.

In plain terms: same goal, different keys, different track records. Sermorelin has a real clinical history; ipamorelin has one PK study and one failed trial ^[2][3]. They are sometimes discussed as alternatives and sometimes as complements, because a GHRP and a GHRH analog hit different receptors. Below, the mechanisms, the evidence, and the honest limits of each.

Different receptors, different signals

The core distinction is receptor-level. Sermorelin binds the GHRH receptor on pituitary somatotrophs, working through the cAMP pathway — the same door the body's natural GHRH uses. Ipamorelin binds GHS-R1a, the ghrelin receptor, working through calcium signaling ^[1]. Because the two act on separate receptors, they are not redundant: a GHRH analog raises the underlying GHRH drive, while a GHRP like ipamorelin adds a discrete pulse on top. That complementarity is exactly why ipamorelin is more often paired with a GHRH analog (CJC-1295) than set against one — see the ipamorelin cjc-1295 stack page. A 2006 clinical review of sermorelin frames the GHRH-analog approach to restoring growth-hormone secretion, useful context for the class sermorelin belongs to ^[12].

Selectivity and the cortisol question

Ipamorelin's signature is selectivity. As a GHRP, it belongs to a family — GHRP-6, GHRP-2 — that historically raised ACTH, cortisol, and prolactin alongside growth hormone. Ipamorelin was engineered out of that problem: even at more than 200 times its growth-hormone ED50, it did not raise ACTH or cortisol above GHRH-induced levels ^[1]. Sermorelin, as a GHRH analog, never had the cortisol-spillover issue to begin with — GHRH analogs act on a pathway that does not drive the stress axis. So on the specific question of off-target hormone activation, both are relatively clean, but for different structural reasons: sermorelin by virtue of its receptor, ipamorelin by virtue of deliberate selectivity engineering.

Evidence base and regulatory status

This is where the two diverge most sharply. Sermorelin reached real clinical use and approval as a GHRH-analog product; ipamorelin never did. Ipamorelin's human evidence is limited to a pharmacokinetic study (n=8/dose, ~2-hour half-life) ^[2] and a single Phase 2 trial for postoperative ileus that missed its primary endpoint (25.3 vs 32.6 hours to first tolerated meal, p=0.15) ^[3]. In 2024, the FDA removed ipamorelin acetate from Category 2 of the interim 503A bulk-substances list and reviewed it at the October 29, 2024 PCAC meeting, restricting compounding access. Both compounds are prohibited in sport under WADA. The practical upshot: if the question is "which one has a documented human track record," sermorelin does; if the question is "which one is the more selective, purely pulsatile growth-hormone trigger," that is ipamorelin's design — but on a much thinner and partly negative human evidence base ^[3].

Can they be combined

Because they act on different receptors, sermorelin (a GHRH analog) and ipamorelin (a GHRP) are mechanistically combinable in the same way CJC-1295 and ipamorelin are — a steady GHRH-side signal plus a pulsatile ghrelin-receptor pulse. The class-level evidence that GHRP + GHRH co-administration can exceed additive growth-hormone release comes from studies of related peptides ^[7][8][9], not from a sermorelin + ipamorelin trial specifically. No controlled human trial has tested that particular pair for any outcome. As with every combination on this site, the mechanism is real and the finished-product evidence is absent — the pairing is a research extrapolation, not a validated protocol.